

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
20 January 2005 (20.01.2005)

PCT

(10) International Publication Number
WO 2005/005454 A1

- (51) International Patent Classification⁷: **C07J 71/00**
- (21) International Application Number:
PCT/EP2004/007537
- (22) International Filing Date: 8 July 2004 (08.07.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
03015502.2 8 July 2003 (08.07.2003) EP
- (71) Applicant (for all designated States except US): **GLY-COMED SCIENCES LIMITED**; P.O.Box 115, Turramurra NSW 2074 (KY).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **LAWSON, Christopher, John** [GB/GB]; Dextra Laboratories, Ltd., Earley Gate, Whiteknights Road, Reading RG6 6BZ (GB). **WEYMOUTH-WILSON, Alexander, Charles** [GB/GB]; Dextra Laboratories, Ltd., Earley Gate, Whiteknights Road, Reading RG6 6BZ (GB).
- (74) Agent: **VOSSIUS & PARTNER**; Siebertstrasse 4, 81675 Munich (DE).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
- with international search report
 - before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

BEST AVAILABLE COPY

(54) Title: **STEROID MODIFIED CHACOTRIOSSES AND SOLATRIOSSES**

(57) Abstract: The present invention relates to steroid modified chacotrioses and the synthesis thereof as well as to intermediate compounds useful for the synthesis of the steroid modified chacotrioses and solatrioses. Moreover, the present invention relates to a method for the preparation of steroid-modified solatrioses.


WO 2005/005454 A1

Steroid modified Chacotrioses and Solatrioses

The present invention relates to the chemical synthesis of alkaloid glycosides, in particular to the synthesis of steroid modified chacotrioses and solatrioses. Furthermore, the present invention relates to intermediate compounds useful for the preparation of steroid modified chacotrioses and solatrioses and to novel steroid modified chacotrioses.


The aglycon solasodine is a source for synthetic cortisone and progesterone. Solasodine and its glycosides are of considerable interest commercially and clinically. They are widely used as starting products for the synthesis of various steroidal drugs.

It is moreover well established that certain naturally occurring conjugate solasodine glycosides have potent antineoplastic properties. Of particular interest is the chacotriose type triglycoside solamargine (22R, 25R)-spiro-5-en-3 β -yl- α -L-rhamnopyranosyl-(1 \rightarrow 2 glu)- α -L-rhamnopyranosyl- (1 \rightarrow 4 glu)- β -D-glucopyranose. The structure of this triglycoside is as follows:



Solamargine

Another naturally occurring conjugate solasodine glycoside of particular interest is the solatriose type triglycoside solasonine (22R, 25R)-spiro-5-en-3 β -yl- α -L-rhamnopyranosyl-(1->2 gal)-O-p-D-glucopyranosyl-(1->3 gal)- β -D-galactopyranose. The structure of this triglycoside is as follows:



Solasonine

The above triglycosides are conventionally obtained by extraction from a plant source. A commercially available extract of *S. sodomaeum*, commonly referred to as BEC (Drug Future, 1988, vol. 13.8, pages 714-716) is a crude mixture of solamargine, solasonine and their isomeric diglycosides. The extraction process for making BEC involves homogenizing the fruits of *S. sodomaeum* in a large volume of acetic acid, filtering off the liquid through muslin followed by precipitation of the glycosides with ammonia (Drugs of today (1990), Vol. 26 No. 1, p. 55-58, cancer letters (1991), Vol. 59, p. 183-192). The yield of the solasodine glycoside mixture is very low (approx. 1%). Moreover the individual process steps are not defined to GMP in terms of scale up, definition of yield, composition and product quality.


There is a great need for a cost efficient process that provides the antineoplastically active triglycosides such as solamargine and solasonine as well as analogues thereof at high yield with little or no impurities.

Contrary to other steroid ring systems, the steroid skeleton of solasodine contains a very labile nitrogen-containing ring. The same hold true for the steroid ring systems of other alkaloids, notably tomatidine, demissidine or solanidine. These aglycons cannot readily be chemically modified while keeping the steroid skeleton intact. In spite of the fact that the aglycon solasodine is readily available, the prior art does not disclose the synthesis of the solamargine or solasonine using the aglycon as starting material.


The problem underlying the present invention is to provide a cost effective method for the preparation of steroid modified chacotrioses and solatrioses such as solamargine and solasonine or analogues thereof in high yields.

Such compounds exhibit cytotoxic activity and may be employed as anticancer agents. Furthermore, such compounds exhibit anti bacterial, anti fungal or anti viral activity.

Accordingly, the present invention provides a method for the preparation of a steroid modified chacotriose of general formula (Ia) or a steroid modified solatriose of general formula (Ib):




Formula (Ia)




Formula (Ib)

wherein R¹ represents a steroid or a derivative thereof having a hydroxyl group in the 3-position and no further unprotected hydroxyl groups; and each R² independently represents a straight or branched C₁₋₁₄ alkyl group, a C₅₋₁₂ aryl or heteroaryl group optionally substituted by one or more halogen atoms or C₁₋₄ alkyl groups, or a hydroxyl group.

The method comprises the step of: reacting a compound of general formula (IIa) or (IIb):




Formula (IIa)




Formula (IIb)

wherein R^3 represents a halogen atom, an ethylsulfide or a phenyl sulfide group; and each R^4 independently represents a benzoyl, substituted benzoyl, whereby the substituents are selected from C_{1-4} alkyl groups, halogen atoms and NO_2 , acetyl or pivoyl protecting group; with a compound of general formula (III):




Formula (III)

wherein R^1 is defined as above; to yield a compound of general formula (IVa) or (IVb):



Formula (IVa)



Formula (IVb)

wherein R^1 and R^4 are defined as above.


The compounds of the above general formulae (IVa) and (IVb) may be transformed to the desired steroid-modified chacotriose of general formula (Ia) or the steroid-modified solatriose of general formula (Ib) by any suitable method known in the art. A particular preferred procedure is described in detail below.

Furthermore, the present application provides steroid modified chacotriose compounds of general formula (Ia) as defined above, wherein R^1 represents a tomatidin-3-yl, demissidin-3-yl group, solanidin-3-yl or solasodin-3-yl group.


A further object of the present application is the provision of intermediate compounds useful for the synthesis of the steroid modified chacotriose of general formula (Ia) defined above, namely:

A compound of general formula (IVa) or (IVb) as defined above;

A compound of general formula (Va) or (Vb):




Formula (Va)




Formula (Vb)

wherein R^1 is defined as above;

A compound of general formula (VIa) or (VIb):




Formula (VIa)




Formula (VIb)

wherein R^1 is as defined above, R^5 represents a pivoly protecting group, and R^6 represents a ketal or acetal type protecting group selected from benzylidene, 4-nitrobenzylidene, 4-methoxybenzylidene or isopropylidene.

A compound of general formula (VIIIa) or (VIIIb):




Formula (VIIIa)



Formula (VIIIb)

wherein R¹, R², R⁴, R⁵ and R⁶ are as defined above.

A compound of general formula (IXb):



Formula (IXb)

wherein R¹, R², R⁴ and R⁶ are as defined above.

Further embodiments of the present application are described in the dependent claims.

Detailed description of the invention

In the following, the present invention will be explained in more detail with reference to preferred embodiments.


The steroid residue constituting substituent R^1 is a steroid or a derivative thereof having a hydroxyl group in the 3-position that serves as the α -glycosidic hydroxyl group, which binds the steroid residue to the compound of formula (II) defined above. The steroid residue bears no further unprotected hydroxyl groups and preferably has no further hydroxyl groups at all, in order not to compromise subsequent reaction steps. In a preferred embodiment of the present invention R^1 is selected from a tomatidin-3-yl, demissidin-3-yl, solanidin-3-yl and solasodin-3-yl group.

All of those steroid groups contain a labile nitrogen-containing ring and, therefore, cannot be chemically modified by means of conventional methods. Moreover, all of the above steroid groups represent substituents for cytotoxic, anti bacterial, anti fungal or anti viral compounds.

In the above general formulae (Ia) and (Ib) each R^2 independently represents a straight or branched C_{1-14} alkyl group, a C_{5-12} aryl or heteroaryl group optionally substituted by one or more halogen atoms or C_{1-4} alkyl groups, or a hydroxyl group. In a preferred embodiment R^2 represents a C_{1-14} alkyl group selected from methyl, ethyl and propyl; an aryl group selected from phenyl, p-methylphenyl and p-chlorophenyl; or an heteroaryl group selected from pyridinyl, pyrimidinyl, furanyl, pyrrolyl, thiophenyl, indolyl, pyrazolyl and imidazolylmethyl; methyl, ethyl and propyl are more preferred.


In a particular preferred embodiment R^2 represents a methyl group.

The method of the present invention for preparing a steroid-modified chacotriose of general formula (Ia) comprises reacting a compound of general formula (IIa):




Formula (IIa)

with a compound of general formula (III):



to yield a compound of general formula (IVa):



Formula (IVa)

In the above general formula (IIa) R^3 represents a halogen atom, an ethylsulfide or a phenyl sulfide group. Preferably, R^3 represents a bromine atom or a chlorine atom. Most preferably R^3 is a bromine atom. Furthermore, in general formulae (IIa) and (IVa), each R^4 independently represents a benzoyl, substituted benzoyl, whereby the substituents are selected from C_{1-4} alkyl groups, halogen atoms and NO_2 , acetyl or pivoyl protecting group, preferably a benzoyl or p-toluoyl protecting group, most preferably a benzoyl protecting group.

The above step is preferably conducted in an inert organic solvent such dichloromethane, tetrahydrofuran or dichloroethane. A preferred solvent is dichloromethane.


Preferably the reaction is carried out in the presence of a promoter. Any conventional promoter used in carbohydrate chemistry may be employed. Particular preferred promoters include silver triflate, boron trifluoride diethyl etherate (-10°C), trimethylsilyl triflate bromide, N-iodosuccinimide and dimethyl thiomethyl sulfonium triflate. The most preferred promoter is silver triflate.

The reaction may preferably be carried out under anhydrous conditions in the presence of a water detracting means such as 4\AA mol sieves.

In a preferred embodiment the reaction is carried out at low temperature such as 0°C or lower, more preferably -10°C or lower. The most preferred reaction temperature is -20°C.

Subsequently, the above-obtained compound of general formula (IVa) may be further modified as described below.

In a preferred embodiment of the method of the present application, the compound of general formula (IVa) is deprotected by removing substituent R⁴ to obtain a compound of general formula (Va):




Formula (Va)

wherein R¹ is defined as above.

Any suitable deprotection condition conventionally employed in the chemistry of protecting groups may be used. Deprotection is preferably carried out in an inert organic solvent such as dichloromethane or tetrahydrofuran in the presence of an alkali metal alkoxide having 1 to 4 carbon atoms and a C₁₋₄ alcohol, or in the presence of water, an alkali metal hydroxide and a C₁₋₄ alcohol. In a particular preferred embodiment deprotection is carried out in dichloromethane in the presence of methanol and sodium methoxide.

The thus obtained compound of general formula (Va) may be selectively protected in 3-OH and 6-OH position using pivoyl chloride in the presence of an amine base to yield compound of general formula (VIa):




Formula (VIa)

wherein R^1 is as defined above, and R^5 represents a pivoly group. Suitable amine bases include pyridine, triethylamine, collidine, or lutidine. A preferred amine base is pyridine.

The reaction may be carried out in an inert organic solvent. Examples of suitable solvents include tetrahydrofuran, dichloroethane, or dimethylformamide.


The compound of formula (VIa) may be then reacted with a compound of general formula (VIIa):



Formula (VIIa)

under substantially the same conditions as described above for the preparation of the compound of formula (IVa). In general formula (VIIa) R^2 , R^3 and R^4 are as defined above.


Resulting compound of general formula (VIIIa):



Formula (VIIIa)

wherein R^1 , R^2 , R^4 and R^5 are as defined above, may be subsequently deprotected to yield the compound of general formula (Ia) under substantially the same conditions as described above for the preparation of the compound of formula (Va). In a preferred this deprotection step is carried out in tetrahydrofuran in the presence of water, sodium hydroxide and methanol.

In another embodiment, the present invention provides a method for preparing a steroid-modified solatriose of general formula (Ib). According to a preferred embodiment of the method for preparing a steroid-modified solatriose of general formula (Ib), galactose is reacted to yield a compound of general formula (IIb):



Formula (IIb)

wherein R^3 and R^4 are as defined above.


The preparation of the compound of formula (IIb) may be carried out using either acetic anhydride, acetyl chloride, benzoyl chloride, benzoic anhydride, or pivoyl chloride in the presence of a base such as, e.g., pyridine, triethylamine, or collidine, to give fully esterified galactose. Esterified-D-galactopyranose may be treated with hydrogenbromide or hydrogenc chloride in glacial acetic acid to yield the above compound of general formula (IIb).

In a particularly preferred embodiment galactose is suspended in organic base such as pyridine and cooled to 0°C , to this solution is added dropwise either acetic anhydride, benzoic anhydride or acid chloride. Upon complete addition the solution is warmed to $+25^{\circ}\text{C}$ (room temperature) and stirred for about 16 hours. The reaction is quenched by addition of alcohol. The solution is diluted with organic solvent such as tert-butylmethyl ether, or dichloromethane, or toluene and washed with cold 1N HCl, water, saturated sodium bicarbonate, water and brine then the product is dried

over magnesium sulfate and concentrated under reduced pressure to dryness. The product can be used without further purification or it can be recrystallised.

The fully esterified galactopyranose in dry solvent such as dichloromethane is cooled to 0°C under an inert atmosphere. To this solution is added hydrogen bromide in glacial acetic acid, typically 30% HBr content. The solution is allowed to warm to +25°C (room temperature) and stirred for around 16 hours. The solution is diluted with organic solvent such as dichloromethane and then quickly washed with ice cold water, saturated aqueous sodium bicarbonate, and brine. The product is dried over magnesium sulfate filtered and the solvent is removed under reduced pressure. The product is crystallized from petrol (40-60) and diethyl ether.

Furthermore, the method for preparing a steroid-modified solatriose of general formula (Ib) comprises reacting the compound of general formula (IIb) as defined above with a compound of general formula (III) as defined above to yield a compound of general formula (IVb):




Formula (IVb)

in which R³ and R⁴ are as defined above.

The step for preparing the compound of formula (IVb) is preferably conducted under substantially the same conditions as the reaction for preparing the compound of formula (IVa) above.

Alternatively, the reaction may be carried out by reacting the compound of formula (III) as defined above with intermediate (A):


13



Intermediate (A)

wherein R^4 is defined above, and R^7 represents any alkyl or aryl residue, e.g., a straight or branched C_{1-14} alkyl group or a phenyl group optionally substituted with one or more C_{1-4} alkyl groups; whereby the C_{1-14} alkyl group is preferably selected from methyl, ethyl and propyl and the phenyl group is preferably selected from phenyl, p-methylphenyl and p-chlorophenyl. The reaction can be carried out in a suitable solvent such as dichloromethane or a combination of dichloromethane and an ether such as diethylether. The reaction is preferably carried out in the presence of a promoter as defined above, e.g., triflic anhydride, and a sterically hindered base such as 2,6-lutidine, 2,4,6-collidine or 2,6-di-tertbutyl-4-methyl pyridine, preferably 2,6-di-t-butylpyridine, at low temperature (below -10°C , preferably below -20°C).

In this embodiment, intermediate (A) may be obtained by oxidizing intermediate (B):




Intermediate (B)

wherein R^4 and R^7 are as defined above, to yield the corresponding sulfoxide (i.e., intermediate (A)). Oxidation of intermediate (B) may be effected using a suitable oxidation means, e.g., m-chloroperbenzoic acid. The reaction may be carried out in a solvent such as dichloromethane at low temperature (-20°C , preferably -40°C).

Intermediate (B) may be formed by the treatment of the compound of formula (IIb) with an alkali metal salt of an alkyl or aryl thiol ($\text{R}^7\text{-SH}$), e.g., the potassium or sodium salt of $\text{R}^7\text{-SH}$, in a suitable solvent such as ethanol or methanol.

Subsequently, the above-obtained compound of general formula (IVb) may be deprotected by removing substituent R^4 to obtain a compound of general formula (Vb):




Formula (Vb)

wherein R^1 is defined as above.

Any suitable deprotection condition conventionally employed in the chemistry of protecting groups may be used. In particular, deprotection may preferably be carried out as described above for the preparation of the compound of formula (Va).

The thus obtained compound of general formula (Va) may be selectively protected in 4-OH and 6-OH position with a ketal or acetal protecting group using standard conditions to yield a compound of general formula (VIb):



Formula (VIb)


wherein R^6 represents a ketal or acetal type protecting group selected from benzylidene, 4-nitrobenzylidene, 4-methoxybenzylidene or isopropylidene. In a preferred embodiment R^7 represents a benzylidene protecting group.

The reaction is preferably carried out in a dipolar aprotic solvent such as dimethyl formamide (DMF) or acetone in the presence of acid catalysts such as p-toluene

sulfonic acid or camphorsulfonic acid using a 2,2-dialkyloxypropane or an optionally substituted dialkyloxybenzylidene such as preferably benzaldehyde dimethyl acetal.

Suitable reaction temperatures range from ambient temperature to elevated temperatures. Preferably the reaction is carried out at a temperature of 25°C.


The compound of formula (VIb) may be then reacted with a compound of general formula (VIIb):



Formula (VIIb)


under substantially the same conditions as described above for the preparation of the compound of formula (IVa). In general formula (VIIb) R³ and R⁴ are as defined above. Selective glycosylation at the more reactive 3-position of the galactose may be achieved at reduced temperature such as 0°C or lower, more preferably -10°C or lower. Most preferably the reaction is carried out at about -20°C.

Resulting compound of general formula (VIIIb):



Formula (VIIIb)

wherein R¹, R⁴ and R⁶ are as defined above, may subsequently be reacted with a compound of formula (VIIa) as defined above under substantially the same conditions as described above for the preparation of the compound of formula (IVa) to yield a compound of general formula (IXb):




Formula (IXb)

wherein R¹, R², R⁴ and R⁶ are as defined above.


Subsequently, the compound of formula (IXb) may be deprotected to yield the compound of formula (Ib). For example, the ester type protecting group R⁴ may be removed at pH 10-11 under substantially the same conditions as described above for the preparation of the compound of formula (Va). The reaction may then be neutralized by addition of solid carbon dioxide. On the other hand, R⁶ may be removed by using catalytic hydrogenation over palladium on carbon and hydrogen in an appropriate solvent such as ethanol or methanol. It should be understood that the removal of R⁴ and the removal of R⁶ are reversible.

Claims

1. A method for the preparation of a steroid modified chacotriose of general formula (Ia) or a steroid modified solatriose of general formula (Ib):



Formula (Ia)




Formula (Ib)


wherein R¹ represents a steroid or a derivative thereof having a hydroxyl group in the 3-position and no further unprotected hydroxyl groups; and each R² independently represents a straight or branched C₁₋₁₄ alkyl group, a C₅₋₁₂ aryl or heteroaryl group optionally substituted by one or more halogen atoms or C₁₋₄ alkyl groups, or a hydroxyl group,

which method comprises the step of:

reacting a compound of general formula (IIa) or (IIb):




Formula (IIa)



Formula (IIb)


wherein R³ represents a halogen atom, an ethylsulfide or a phenyl sulfide group; and each R⁴ independently represents a benzoyl, substituted benzoyl, whereby the substituents are selected from C₁₋₄ alkyl groups, halogen atoms and NO₂, acetyl or pivoyl protecting group; with a compound of general formula (III):




Formula (III)

wherein R^1 is defined as above;

to yield a compound of general formula (IVa) or (IVb):




Formula (IVa)




Formula (IVb)

wherein R^1 and R^4 are defined as above.

2. The method according to claim 1, further comprising the step of:
deprotecting the compound of general formula (IVa) or (IVb), respectively, as
defined in claim 1 to yield a compound of general formula (Va) or (Vb):




Formula (Va)



Formula (Vb)

wherein R^1 is as defined in claim 1.


3. The method according to claim 1 or 2 for preparing a steroid modified
chacotriose of general formula (Ia), further comprising the step of:
reacting the compound of general formula (Va) as defined in claim 2 with pivoyl
chloride in the presence of an amine base to yield a compound of general
formula (VIa):



Formula (VIa)


wherein R^1 is as defined in claim 1, and R^5 represents a pivoly protecting group.

4. The method according to any of claims 1 to 3 for preparing a steroid modified chacotriose of general formula (Ia), further comprising the step of:
 reacting the compound of general formula (VIa) as defined in claim 3 with a compound of general formula (VIIa):



Formula (VIIa)

wherein R^2 , R^3 and R^4 are as defined in claim 1;
 to yield a compound general formula (VIIIa):




Formula (VIIIa)

wherein R^1 , R^2 and R^4 are as defined in claim 1, and R^5 is as defined in claim 3.

5. The method according of any of claims 1 to 4 for preparing a steroid modified chacotriose of general formula (Ia), further comprising the step of:
 deprotecting the compound of general formula (VIIIa) as defined in claim 4 to
 yield the compound of general formula (Ia).


6. The method according to claim 1 or 2 for preparing a steroid modified solatriose of general formula (Ib), further comprising the step of:
selectively protecting the OH groups in 4- and 6-position of the compound of formula (Vb) as defined in claim 2 with a ketal or acetal protecting type protecting group using standard conditions, to yield a compound of general formula (VIb):



Formula (VIb)


wherein R^1 is as defined in claim 1, and R^6 represents a ketal or acetal type protecting group selected from the group consisting of benzylidene, 4-nitrobenzylidene, 4-methoxybenzylidene and isopropylidene.

7. The method according to any of claims 1, 2 or 6 for preparing a steroid modified solatriose of general formula (Ib), further comprising the step of:
reacting a compound of formula (VIb) as defined in claim 6 with a compound of general formula (VIIb):



Formula (VIIb)


wherein R^3 and R^4 are as defined in claim 1,
to yield a compound general formula (VIIIb):



Formula (VIIIb)

wherein R^1 and R^4 are as defined in claim 1, and R^6 is as defined in claim 6.

8. The method according to any of claims 1, 2, 6 or 7 for preparing a steroid modified solatriose of general formula (Ib), further comprising the step of: reacting a compound of formula (VIIIb) as defined in claim 7 with a compound of formula (VIIa) as defined in claim 4 to yield a compound of formula (IXb):



Formula (IXb)

wherein R^1 , R^2 and R^4 are as defined in claim 1, and R^6 is as defined in claim 6.

9. The method according to any of claims 1, 2, 6, 7 or 8 for preparing a steroid modified solatriose of general formula (Ib), further comprising the step of: deprotecting the compound of formula (IXb) as defined in claim 8 to yield the compound of formula (Ib).
10. The method according to any of the preceding claims, wherein R^1 represents a tomatidin-3-yl, demissidin-3-yl, solanidin-3-yl and solasodin-3-yl group.

11. The method according to any of the preceding claims, wherein R^2 represents a methyl group.
12. The method according to any of the preceding claims, wherein R^3 in the compounds of formulae (IIa), (IIb), (VIIa) and/or (VIIb) represents a bromine atom.
13. The method according to any of claims 1, 4, 7 or 8, wherein the reaction is carried out in the presence of a promoter.
14. The method according to claim 13, wherein the promoter is selected from the group consisting of silver triflate, boron trifluoride diethyl etherate, trimethylsilyl triflate bromide, N-iodosuccinimide and dimethyl thiomethyl sulfonium triflate.
15. The method according to claim 14, wherein the promoter is silver triflate.
16. The method according to any of claims 1, 4, 7 or 8, wherein the reaction is carried out under anhydrous conditions in the presence of 4Å mol sieves.
17. The method according to claim 2 or 5, wherein deprotection is carried out in dichloromethane or tetrahydrofuran in the presence of a C_{1-4} alcohol and an alkali metal alkoxide having 1 to 4 carbon atoms.
18. The method according to claim 17, wherein deprotection is carried out in dichloromethane in the presence of methanol and sodium methoxide.
19. The method according to claim 2 or 5, wherein deprotection is carried out in dichloromethane or tetrahydrofuran in the presence of water, an alkali metal hydroxide and a C_{1-4} alcohol.
20. The method according to claim 19, wherein deprotection is carried out in tetrahydrofuran, and wherein the alkali metal hydroxide is sodium hydroxide and the alcohol is methanol.

21. The method according to claim 1 for preparing a steroid modified solatriose of general formula (Ib), wherein R^4 represents a benzoyl or p-toluoyl protecting group.
22. The method according to any of the preceding claims, wherein reacting a ~~compound of general formula (IIa) or (IIb)~~ with a compound of general formula (III) is carried out in the presence of sterically hindered non-nucleophilic base.
23. The method according to claim 22, wherein the sterically hindered non-nucleophilic base is selected from 2,6-lutidine, 2,4,6-collidine or 2,6-di-tertbutyl-4-methyl pyridine.
24. A steroid modified chacotriose of general formula (Ia) as defined in claim 1 or 11, wherein R^1 represents a tomatidin-3-yl or demissidin-3-yl group.
25. A compound of general formula (VIIIa) as defined in any of claims 4, 10 or 11;
a compound of general formula (VIIIb) as defined in any of claims 7, 10 or 11;
a compound of general formula (VIa) as defined in any of claims 3, 10 or 11;
a compound of general formula (VIb) as defined in any of claims 6, 10 or 11;
a compound of general formula (Va) or (Vb) as defined in any of claims 2, 10 or 11;
a compound of general formula (IVa) or (IVb) as defined in any of claims 1, 10 or 11; or
a compound of general formula (IXb) as defined in any of claims 8, 10 or 11.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2004/007537

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07J71/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07J

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 03/018604 A (GLYCOMED SCIENCES LTD ; SHAHID MOHAMMED (GB)) 6 March 2003 (2003-03-06)	1-5, 10-23, 25
Y	the whole document	24
X	LI B ET AL: "An improved synthesis of the saponin, polyphyllin D" CARBOHYDRATE RESEARCH, ELSEVIER SCIENTIFIC PUBLISHING COMPANY. AMSTERDAM, NL, vol. 331, no. 1, 9 March 2001 (2001-03-09), pages 1-7, XP004317141 ISSN: 0008-6215 scheme 1 compounds 1,2	25

-/--

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

29 November 2004

Date of mailing of the international search report

16/12/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Friebel, F

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP2004/007537

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BITE P ET AL: "PREPARATION OF STEROID GLYCOSIDES" ACTA CHIMICA ACADEMIAE SCIENTIARUM HUNGARICA, BUDAPEST, HU, vol. 52, no. 1, 1967, pages 79-82, XP001127494 ISSN: 0001-5407 the whole document -----	25
X	PACZKOWSKI C ET AL: "GLUCOSYLATION AND GALACTOSYLATION OF DIOSGENIN AND SOLASODINE BY SOLUBLE GLYCOSYLTRANSFERASE(S) FROM SOLANUM MELONGENA LEAVES" PHYTOCHEMISTRY, PERGAMON PRESS, GB, vol. 35, no. 6, 19 April 1994 (1994-04-19), pages 1429-1434, XP001132072 ISSN: 0031-9422 table 1 -----	25
E	WO 2004/096830 A (SHAHID MOHAMMED ; GLYCOMED SCIENCES UK LTD (GB)) 11 November 2004 (2004-11-11) the whole document -----	6-9
Y	MIN-JWEI SHIH ET AL.: "alpha- and beta-Solamarine in Kennebec Solanum Tuberosum Leaves and aged Tuber Slices" PHYTOCHEMISTRY, vol. 13, 1974, pages 997-1000, XP002308073 the whole document -----	24

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 03018604	A	06-03-2003	BR 0212397 A	19-10-2004
			CA 2458183 A1	06-03-2003
			WO 03018604 A1	06-03-2003
			EP 1421100 A1	26-05-2004
<hr/>				
WO 2004096830	A	11-11-2004	WO 2004096830 A1	11-11-2004
<hr/>				

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.